GLP-1 Injections Under Scrutiny: Why Medical Oversight Matters More Than Ever

Dr David Grieve

The conversation around GLP-1 weight loss injections has reached a critical point. 

In a recent interview on Goeiemôre Good Morning, aesthetic practitioner Dr David Grieve joined the discussion following a controversial report involving the sale and marketing of GLP-1 medications such as Ozempic and Mounjaro by non-medical individuals. 

What began as a single complaint has opened up a much broader and more pressing industry conversation. 

At the heart of the discussion lies a key question: Who should be allowed to prescribe, sell, and administer these treatments? 

As demand for rapid weight loss solutions continues to surge, GLP-1 agonists have become one of the most talked-about treatments across both medical and aesthetic spaces. However, with popularity has come confusion, misinformation, and growing concern around patient safety. 

Dr Grieve addressed a number of critical issues, including the misconception that peptides and similar products fall into the same category as over-the-counter supplements. In reality, these are potent medical treatments that require proper clinical oversight, patient assessment, and ongoing monitoring. 

The risks of unsupervised use are not insignificant. From unmanaged side effects to inappropriate patient selection, the consequences of incorrect use can be severe, particularly when treatments are administered outside of a regulated medical framework. 

Beyond the clinical risks, the discussion also touched on a wider industry trend: the increasing normalisation of “quick-fix” solutions driven by social media demand. While patient interest continues to grow, so too does the responsibility on practitioners and regulatory bodies to ensure ethical practice and patient-first care. 

Dr Grieve’s message was clear. There is an urgent need for clarity, regulation, and accountability within this rapidly evolving space. 

Hear More at the Aesthetic Medicine Convention 

Dr David Grieve will be speaking at the Aesthetic Medicine Convention Johannesburg, where he will expand on these critical topics as part of the Qualified Medical Practitioners Programme. 

📅 Day 1 – 15 May 2026 🕒 11:00 – 13:00 📍 Peptides: The Future of Aesthetic Medicine 

Topic: Regulatory Landscape and Patient Safety Considerations 

Secure Your Seat 

The Aesthetic Medicine Convention is now less than a week away. 

Join leading experts, gain critical regulatory insight, and stay ahead in an increasingly complex and fast-moving industry. 

Extended Early Bird – Save 25% (ending soon): 

Qualified Medical Practitioners  

2 Days – R3 375 (Save R1 125)  

1 Day – R2 625 (Save R875)  

Aesthetic Medicine Practice Staff  

2 Days – R1 875 (Save R625)  

1 Day – R1 125 (Save R375)  

Doctors attending the 2-day programme can earn 12 CPD points (10 Clinical, 2 Ethical). 

Book a two-day ticket and stand a chance to win your money back plus R2,000 cash. 

Seats are limited. 

Book now to secure your place.